• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

Recombinant Human Golgin-45 (BLZF1)

ACP11549

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ACP11549 Target NameBLZF1
FormLyophilized powderExpression SystemCustom Production. Please inquire and provide the desire expression system.
Expression Range1-400Protein LengthFull length protein
Purity>85% (SDS-PAGE)Storage Buffer5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, Liquid form: default storage buffer is Tris/PBS-based buffer, pH 8.0.

Immunogen Information


Target SpeciesHumanUniprot IDQ9H2G9
Background Information
  • Uniprot Id

    Q9H2G9

  • Target Species

    Human

  • Target Name

    BLZF1

  • Target Full Name

    Golgin-45

  • Target Function

    Required for normal Golgi structure and for protein transport from the endoplasmic reticulum (ER) through the Golgi apparatus to the cell surface.

  • Target Subcellular Location

    Golgi apparatus membrane.; [Isoform 1]: Nucleus.; [Isoform 2]: Cytoplasm.

  • Target Tissue Specificity

    Detected in adrenal gland.

  • Target Synonyms

    1700030G05Rik; basic leucine zipper nuclear factor 1 (JEM 1); Basic leucine zipper nuclear factor 1; BLZF1; Blzf1l; GO45_HUMAN; GOLGIN 45; Golgin-45; JEM 1; JEM 1s; JEM-1; JEM1; MGC22497 ; p45 basic leucine zipper nuclear factor; p45 basic leucine-zipper nuclear factor

  • Target Background

    Enables ubiquitin protein ligase binding activity. Acts upstream of or within Golgi organization and Golgi to plasma membrane protein transport. Located in Golgi apparatus and nucleoplasm. Biomarker of hepatocellular carcinoma.

Inquire Recombinant Human Golgin-45 (BLZF1) Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification